1
|
Afify AF, Hassanien RT, El Naggar RF, Rohaim MA, Munir M. Unmasking the ongoing challenge of equid herpesvirus- 1 (EHV-1): A comprehensive review. Microb Pathog 2024; 193:106755. [PMID: 38897362 DOI: 10.1016/j.micpath.2024.106755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2023] [Revised: 06/01/2024] [Accepted: 06/17/2024] [Indexed: 06/21/2024]
Abstract
Equid herpesviruses (EHVs) are a group of highly impactful viral pathogens that affect horses, presenting a substantial risk to the global equine industry. Among these, equid herpesvirus-1 (EHV-1) primarily causes respiratory infections. However, its ability to spread to distant organs can lead to severe consequences such as abortion and neurological diseases. These viruses can enter a dormant phase, with minimal activity, and later reactivate to trigger active infections at any time. Recently, there has been a notable rise in the prevalence of a particularly devastating strains of EHV-1 known as equid herpesviral myeloencephalopathy (EHM). In the light of dynamic nature of EHV-1, this review provides a thorough overview of EHV-1 and explores how advances in viral biology affect the pathophysiology of viral infection. The information presented here is crucial for understanding the dynamics of EHV-1 infections and creating practical plans to stop the virus's global spread among equid populations.
Collapse
Affiliation(s)
- Ahmed F Afify
- Department of Virology, Animal Health Research Institute, Agriculture Research Center (ARC), Giza, 12618, Egypt
| | - Rabab T Hassanien
- Department of Virology, Animal Health Research Institute, Agriculture Research Center (ARC), Giza, 12618, Egypt
| | - Rania F El Naggar
- Department of Virology, Faculty of Veterinary Medicine, University of Sadat City, Sadat, 32897, Egypt
| | - Mohammed A Rohaim
- Department of Virology, Faculty of Veterinary Medicine, Cairo University, Giza, 12211, Egypt; Division of Biomedical and Life Science, Lancaster University, Lancaster, LA1 4YG, UK
| | - Muhammad Munir
- Division of Biomedical and Life Science, Lancaster University, Lancaster, LA1 4YG, UK.
| |
Collapse
|
2
|
Normand C, Thieulent CJ, Fortier C, Sutton G, Senamaud-Beaufort C, Jourdren L, Blugeon C, Vidalain PO, Pronost S, Hue ES. A Screening Study Identified Decitabine as an Inhibitor of Equid Herpesvirus 4 That Enhances the Innate Antiviral Response. Viruses 2024; 16:746. [PMID: 38793627 PMCID: PMC11125953 DOI: 10.3390/v16050746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2024] [Revised: 04/18/2024] [Accepted: 05/02/2024] [Indexed: 05/26/2024] Open
Abstract
Equid herpesvirus 4 (EHV-4) is a common respiratory pathogen in horses. It sporadically induces abortion or neonatal death. Although its contribution in neurological disorders is not clearly demonstrated, there is a strong suspicion of its involvement. Despite preventive treatments using vaccines against EHV-1/EHV-4, the resurgence of alpha-EHV infection still constitutes an important threat to the horse industry. Yet very few studies have been conducted on the search for antiviral molecules against EHV-4. A screening of 42 antiviral compounds was performed in vitro on equine fibroblast cells infected with the EHV-4 405/76 reference strain (VR2230). The formation of cytopathic effects was monitored by real-time cell analysis (RTCA), and the viral load was quantified by quantitative PCR. Aciclovir, the most widely used antiviral against alpha-herpesviruses in vivo, does not appear to be effective against EHV-4 in vitro. Potential antiviral activities were confirmed for eight molecules (idoxuridine, vidarabine, pritelivir, cidofovir, valganciclovir, ganciclovir, aphidicolin, and decitabine). Decitabine demonstrates the highest efficacy against EHV-4 in vitro. Transcriptomic analysis revealed the up-regulation of various genes implicated in interferon (IFN) response, suggesting that decitabine triggers the immune antiviral pathway.
Collapse
Affiliation(s)
- Camille Normand
- LABÉO, 14280 Saint-Contest, France
- Normandie Université, UNICAEN BIOTARGEN, 14280 Saint-Contest, France
| | - Côme J. Thieulent
- Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA;
- Louisiana Animal Disease Diagnostic Laboratory, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA
| | - Christine Fortier
- LABÉO, 14280 Saint-Contest, France
- Normandie Université, UNICAEN BIOTARGEN, 14280 Saint-Contest, France
- Normandie Université, UNICAEN, ImpedanCELL, 14280 Saint-Contest, France
| | - Gabrielle Sutton
- Cytokines and Adaptive Immunity Lab, Sainte-Justine University Hospital and Research Center, University of Montréal, Montreal, QC H3T 1C5, Canada
- Microbiology, Infectiology and Immunology Department, Faculty of Medicine, University of Montréal, Montreal, QC H3T 1C5, Canada
| | - Catherine Senamaud-Beaufort
- GenomiqueENS, Institut de Biologie de l’ENS (IBENS), Département de Biologie, École Normale Supérieure, CNRS, INSERM, Université PSL, 75005 Paris, France
| | - Laurent Jourdren
- GenomiqueENS, Institut de Biologie de l’ENS (IBENS), Département de Biologie, École Normale Supérieure, CNRS, INSERM, Université PSL, 75005 Paris, France
| | - Corinne Blugeon
- GenomiqueENS, Institut de Biologie de l’ENS (IBENS), Département de Biologie, École Normale Supérieure, CNRS, INSERM, Université PSL, 75005 Paris, France
| | - Pierre-Olivier Vidalain
- Team Viral Infection, Metabolism and Immunity, Centre International de Recherche en Infectiologie (CIRI), Univ Lyon, Institut National de la Santé et de la Recherche Médicale (Inserm), U1111, Centre National de la Recherche Scientifique (CNRS), UMR5308, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, 69007 Lyon, France
| | - Stéphane Pronost
- LABÉO, 14280 Saint-Contest, France
- Normandie Université, UNICAEN BIOTARGEN, 14280 Saint-Contest, France
- Normandie Université, UNICAEN, ImpedanCELL, 14280 Saint-Contest, France
| | - Erika S. Hue
- LABÉO, 14280 Saint-Contest, France
- Normandie Université, UNICAEN BIOTARGEN, 14280 Saint-Contest, France
- Normandie Université, UNICAEN, ImpedanCELL, 14280 Saint-Contest, France
| |
Collapse
|
3
|
Soboll‐Hussey G, Dorman DC, Burgess BA, Goehring L, Gross P, Neinast C, Osterrieder K, Pusterla N, Lunn DP. Relationship between equine herpesvirus-1 viremia and abortion or equine herpesvirus myeloencephalopathy in domesticated horses: A systematic review. J Vet Intern Med 2024; 38:1872-1891. [PMID: 38069576 PMCID: PMC11099755 DOI: 10.1111/jvim.16948] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2023] [Accepted: 11/09/2023] [Indexed: 05/18/2024] Open
Abstract
BACKGROUND Equine herpes virus type 1 (EHV-1) infection in horses is associated with upper respiratory disease, neurological disease, abortions, and neonatal death. OBJECTIVE To determine if there is an association between the level and duration of EHV-1 viremia and either abortion or equine herpesvirus myeloencephalopathy (EHM) in domesticated horses? METHODS A systematic review was performed searching numerous databases to identify peer reviewed reports that evaluated viremia and EHM, or viremia and abortion published before January 19, 2021. Randomized controlled trials and observational studies were assessed for risk of bias or publication quality. RESULTS A total of 189 unique studies were identified, of which 34 met the inclusion criteria. Thirty studies evaluated viremia and neurologic outcomes including 4 observational studies. Eight experimental studies examined viremia and abortion, which used the Ab4 and OH03 virus strains or recombinant Ab4 derivatives. Incidence rates for both EHM and abortion in experimental studies varied among the studies as did the level of evidence. Viremia was generally detectable before the onset of either EHM or abortion. Risk of bias was generally low to moderate, sample sizes were small, and multiple studies reported negative outcome data. CONCLUSIONS AND CLINICAL IMPORTANCE The results of this study support that viremia is regularly present before EHM or abortion occurs. However, no inferences could be made about the relationship between the occurrence of either neurological signs or abortion and the magnitude or duration of viremia.
Collapse
Affiliation(s)
- Gisela Soboll‐Hussey
- College of Veterinary MedicineMichigan State University, Veterinary Medical Center, Room G331, 784 Wilson RoadEast Lansing, Michigan 48824USA
| | - David C. Dorman
- College of Veterinary MedicineNorth Carolina State University, 1060 William Moore DriveRaleigh, North Carolina 27607USA
| | - Brandy A. Burgess
- College of Veterinary MedicineUniversity of Georgia, 2200 College Station RoadAthens, Georgia 30602USA
| | - Lutz Goehring
- College of Agriculture, Food and Environment, Maxwell H. Gluck Equine Research Center, University of Kentucky, 1400 Nicholasville RoadLexington, Kentucky 40546‐0099USA
| | - Peggy Gross
- College of Veterinary MedicineNorth Carolina State University, 1060 William Moore DriveRaleigh, North Carolina 27607USA
| | - Claire Neinast
- College of Veterinary MedicineNorth Carolina State University, 1060 William Moore DriveRaleigh, North Carolina 27607USA
| | - Klaus Osterrieder
- Institut für Virologie, Freie Universität Berlin, Robert‐von‐Ostertag‐Strasse 7Berlin 14163Germany
| | - Nicola Pusterla
- School of Veterinary MedicineUniversity of California, Davis, One Garrod DriveDavis, California 95616USA
| | - David P. Lunn
- School of Veterinary ScienceUniversity of Liverpool, Leahurst Campus, Chester High RoadNeston CH64 7TEUnited Kingdom
| |
Collapse
|
4
|
Pusterla N, Dorman DC, Burgess BA, Goehring L, Gross M, Osterrieder K, Soboll Hussey G, Lunn DP. Viremia and nasal shedding for the diagnosis of equine herpesvirus-1 infection in domesticated horses. J Vet Intern Med 2024; 38:1765-1791. [PMID: 38069548 PMCID: PMC11099742 DOI: 10.1111/jvim.16958] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Accepted: 11/16/2023] [Indexed: 05/18/2024] Open
Abstract
BACKGROUND Equine herpesvirus type 1 (EHV-1) infection is associated with upper respiratory disease, EHM, abortions, and neonatal death. RESEARCH QUESTIONS Are nasal secretions a more sensitive biological sample compared to blood for the detection of EHV-1 infection? How long is EHV-1 detectable after primary infection by PCR? METHODS MedLine and Web of Science searches identified original peer-reviewed reports evaluating nasal shedding and viremia using virus isolation methods or PCR published in English before October 9, 2023. RESULTS Sixty experimental and 20 observational studies met inclusion criteria. EHV-1 detection frequency by qPCR in nasal secretions and blood from naturally-infected horses with fever and respiratory signs were 15% and 9%, respectively; qPCR detection rates in nasal secretions and blood from horses with suspected EHM were 94% and 70%, respectively. In experimental studies the sensitivity of qPCR matched or exceeded that seen for virus isolation from either nasal secretions or blood. Detection of nasal shedding typically occurred within 2 days after EHV-1 inoculation with a detection period of 3 to 7 days. Viremia lasted 2 to 7 days and was usually detected ≥1 days after positive identification of EHV-1 in nasal secretions. Nasal shedding and viremia decreased over time and remained detectable in some horses for several weeks after inoculation. CONCLUSIONS AND CLINICAL IMPORTANCE Under experimental conditions, blood and nasal secretions have similar sensitivity for the detection of EHV-1 when horses are sampled on multiple consecutive days. In contrast, in observational studies detection of EHV-1 in nasal secretions was consistently more successful.
Collapse
Affiliation(s)
- Nicola Pusterla
- School of Veterinary MedicineUniversity of CaliforniaDavisCaliforniaUSA
| | - David C. Dorman
- College of Veterinary MedicineNorth Carolina State UniversityRaleighNorth CarolinaUSA
| | | | - Lutz Goehring
- College of Agriculture, Food and Environment, Maxwell H. Gluck Equine Research CenterUniversity of KentuckyLexingtonKentuckyUSA
| | - Margaret Gross
- College of Veterinary MedicineNorth Carolina State UniversityRaleighNorth CarolinaUSA
| | | | - Gisela Soboll Hussey
- College of Veterinary MedicineMichigan State University, Veterinary Medical CenterEast LansingMichiganUSA
| | - David P. Lunn
- School of Veterinary ScienceUniversity of Liverpool, Leahurst CampusNestonUK
| |
Collapse
|
5
|
Goehring L, Dorman DC, Osterrieder K, Burgess BA, Dougherty K, Gross P, Neinast C, Pusterla N, Soboll‐Hussey G, Lunn DP. Pharmacologic interventions for the treatment of equine herpesvirus-1 in domesticated horses: A systematic review. J Vet Intern Med 2024; 38:1892-1905. [PMID: 38380685 PMCID: PMC11099759 DOI: 10.1111/jvim.17016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Accepted: 01/30/2024] [Indexed: 02/22/2024] Open
Abstract
BACKGROUND Equine herpes virus type 1 (EHV-1) infection in horses is associated with upper respiratory disease, neurological disease, abortions, and neonatal death. REVIEW QUESTION Does pharmacological therapy decrease either the incidence or severity of disease or infection caused by EHV-1 in domesticated horses? METHODS A systematic review was preformed searching AGRICOLA, CAB Abstracts, Cochrane, PubMed, Web of Science, and WHO Global Health Index Medicus Regional Databases to identify articles published before February 15, 2021. Selection criteria were original research reports published in peer reviewed journals, and studies investigating in vivo use of therapeutic agents for prevention or treatment of EHV-1 in horses. Outcomes assessed included measures related to clinical outcomes that reflect symptomatic EHV-1 infection or virus infection. We evaluated risk of bias and performed a GRADE evaluation of the quality of evidence for interventions. RESULTS A total of 7009 unique studies were identified, of which 9 met the inclusion criteria. Two studies evaluated valacyclovir or small interfering RNAs, and single studies evaluated the use of a Parapoxvirus ovis-based immunomodulator, human alpha interferon, an herbal supplement, a cytosine analog, and heparin. The level of evidence ranged between randomized controlled studies and observational trials. The risk of bias was moderate to high and sample sizes were small. Most studies reported either no benefit or minimal efficacy of the intervention tested. CONCLUSIONS AND CLINICAL IMPORTANCE Our review indicates minimal or limited benefit either as a prophylactic or post-exposure treatment for any of the studied interventions in the mitigation of EHV-1-associated disease outcome.
Collapse
Affiliation(s)
- Lutz Goehring
- University of Kentucky, College of Agriculture, Food and Environment, Maxwell H. Gluck Equine Research Center, 1400 Nicholasville RoadLexington, Kentucky 40546‐0099USA
| | - David C. Dorman
- College of Veterinary Medicine, North Carolina State University, 1060 William Moore DriveRaleigh, North Carolina 27607USA
| | - Klaus Osterrieder
- Institut für Virologie, Freie Universität Berlin, Robert‐von‐Ostertag‐Str. 714163 BerlinGermany
| | - Brandy A. Burgess
- College of Veterinary MedicineUniversity of Georgia, 2200 College Station RoadAthens, Georgia 30602USA
| | - Kelsie Dougherty
- College of Veterinary Medicine, North Carolina State University, 1060 William Moore DriveRaleigh, North Carolina 27607USA
| | - Peggy Gross
- College of Veterinary Medicine, North Carolina State University, 1060 William Moore DriveRaleigh, North Carolina 27607USA
| | - Claire Neinast
- College of Veterinary Medicine, North Carolina State University, 1060 William Moore DriveRaleigh, North Carolina 27607USA
| | - Nicola Pusterla
- School of Veterinary Medicine, University of California, Davis, One Garrod DriveDavis, California 95616USA
| | - Gisela Soboll‐Hussey
- College of Veterinary Medicine, Michigan State University, Veterinary Medical Center, Room G331, 784 Wilson RoadEast Lansing, Michigan 48824USA
| | - David P. Lunn
- School of Veterinary Science, University of Liverpool, Leahurst Campus, Chester High RoadNeston CH64 7TEUnited Kingdom
| |
Collapse
|
6
|
Velloso Alvarez A, Jose-Cunilleras E, Dorrego-Rodriguez A, Santiago-Llorente I, de la Cuesta-Torrado M, Troya-Portillo L, Rivera B, Vitale V, de Juan L, Cruz-Lopez F. Detection of equine herpesvirus-1 (EHV-1) in urine samples during outbreaks of equine herpesvirus myeloencephalopathy. Equine Vet J 2024; 56:456-463. [PMID: 37699794 DOI: 10.1111/evj.14007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Accepted: 08/17/2023] [Indexed: 09/14/2023]
Abstract
BACKGROUND Real-time PCR is the diagnostic technique of choice for the diagnosis and control of equine herpesvirus-1 (EHV-1) in an outbreak setting. The presence of EHV-1 in nasal swabs (NS), whole blood, brain and spinal cord samples has been extensively described; however, there are no reports on the excretion of EHV-1 in urine, its DNA detection patterns, and the role of urine in viral spread during an outbreak. OBJECTIVES To determine the presence of EHV-1 DNA in urine during natural infection and to compare the DNA detection patterns of EHV-1 in urine, buffy coat (BC) and NS. STUDY DESIGN Descriptive study of natural infection. METHODS Urine and whole blood/NS samples were collected at different time points during the hospitalisation of 21 horses involved in two EHV-1 myeloencephalopathy outbreaks in 2021 and 2023 in Spain. Quantitative real-time PCR was performed to compare the viral DNA load between BC-urine samples in 2021 and NS-urine samples in 2023. Sex, age, breed, presence of neurological signs, EHV-1 vaccination status and treatment data were recorded for all horses. RESULTS A total of 18 hospitalised horses during the 2021 and 2023 outbreaks were positive for EHV-1, and viral DNA was detected in urine samples from a total of 11 horses in both outbreaks. Compared with BC samples, DNA presence was detected in urine samples for longer duration and with slightly higher concentration; however, compared with NS, detection of EHV-1 in urine was similar in duration with lower DNA concentrations. MAIN LIMITATIONS Limited sample size, different sampling times and protocols (BC vs. NS) in two natural infection outbreak settings. CONCLUSIONS EHV-1 was detected in the urine from naturally infected horses. Urine should be considered as complimentary to blood and NS in diagnosis of EHV-1 infection.
Collapse
Affiliation(s)
| | - E Jose-Cunilleras
- Unitat Equina, Fundació Hospital Clínic Veterinari, Cerdañola del Valles, Spain
- Department of Animal Medicine and Surgery, Universitat Autònoma de Barcelona, Cerdañola del Valles, Spain
| | | | | | | | - Lucas Troya-Portillo
- Unitat Equina, Fundació Hospital Clínic Veterinari, Cerdañola del Valles, Spain
- Department of Animal Medicine and Surgery, Universitat Autònoma de Barcelona, Cerdañola del Valles, Spain
| | - Belen Rivera
- VISAVET Health Surveillance Centre, Universidad Complutense, Madrid, Spain
| | | | - Lucia de Juan
- VISAVET Health Surveillance Centre, Universidad Complutense, Madrid, Spain
- Animal Health Department, Facultad de Veterinaria, Universidad Complutense, Madrid, Spain
| | - Fatima Cruz-Lopez
- VISAVET Health Surveillance Centre, Universidad Complutense, Madrid, Spain
| |
Collapse
|
7
|
Giessler KS, Goehring LS, Jacob SI, Davis A, Esser MM, Lee Y, Zarski LM, Weber PSD, Hussey GS. Impact of the host immune response on the development of equine herpesvirus myeloencephalopathy in horses. J Gen Virol 2024; 105:001987. [PMID: 38767608 PMCID: PMC11170125 DOI: 10.1099/jgv.0.001987] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2024] [Accepted: 04/25/2024] [Indexed: 05/22/2024] Open
Abstract
Herpesviruses establish a well-adapted balance with their host's immune system. Despite this co-evolutionary balance, infections can lead to severe disease including neurological disorders in their natural host. In horses, equine herpesvirus 1 (EHV-1) causes respiratory disease, abortions, neonatal foal death and myeloencephalopathy (EHM) in ~10 % of acute infections worldwide. Many aspects of EHM pathogenesis and protection from EHM are still poorly understood. However, it has been shown that the incidence of EHM increases to >70 % in female horses >20 years of age. In this study we used old mares as an experimental equine EHV-1 model of EHM to identify host-specific factors contributing to EHM. Following experimental infection with the neuropathogenic strain EHV-1 Ab4, old mares and yearling horses were studied for 21 days post-infection. Nasal viral shedding and cell-associated viremia were assessed by quantitative PCR. Cytokine/chemokine responses were evaluated in nasal secretions and cerebrospinal fluid (CSF) by Luminex assay and in whole blood by quantitative real-time PCR. EHV-1-specific IgG sub-isotype responses were measured by ELISA. All young horses developed respiratory disease and a bi-phasic fever post-infection, but only 1/9 horses exhibited ataxia. In contrast, respiratory disease was absent in old mares, but all old mares developed EHM that resulted in euthanasia in 6/9 old mares. Old mares also presented significantly decreased nasal viral shedding but higher viremia coinciding with a single fever peak at the onset of viremia. According to clinical disease manifestation, horses were sorted into an EHM group (nine old horses and one young horse) and a non-EHM group (eight young horses) for assessment of host immune responses. Non-EHM horses showed an early upregulation of IFN-α (nasal secretions), IRF7/IRF9, IL-1β, CXCL10 and TBET (blood) in addition to an IFN-γ upregulation during viremia (blood). In contrast, IFN-α levels in nasal secretions of EHM horses were low and peak levels of IRF7, IRF9, CXCL10 and TGF-β (blood) coincided with viremia. Moreover, EHM horses showed significantly higher IL-10 levels in nasal secretions, peripheral blood mononuclear cells and CSF and higher serum IgG3/5 antibody titres compared to non-EHM horses. These results suggest that protection from EHM depends on timely induction of type 1 IFN and upregulation cytokines and chemokines that are representative of cellular immunity. In contrast, induction of regulatory or TH-2 type immunity appeared to correlate with an increased risk for EHM. It is likely that future vaccine development for protection from EHM must target shifting this 'at-risk' immunophenotype.
Collapse
Affiliation(s)
- K. S. Giessler
- Department of Pathobiology & Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
| | - L. S. Goehring
- MH Gluck Equine Research Center, College of Agriculture, Food & Environment, University of Kentucky, Lexington, KY, USA
| | - S. I. Jacob
- Department of Pathobiology & Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA
| | - Allison Davis
- Department of Pathobiology & Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA
| | - M. M. Esser
- Department of Pathobiology & Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA
| | - Y. Lee
- Pathology Core, Unit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, MI, USA
| | - L. M. Zarski
- Department of Pathobiology & Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA
| | - P. S. D. Weber
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA
| | - G. S. Hussey
- Department of Pathobiology & Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA
| |
Collapse
|
8
|
Mannini A, Ellero N, Urbani L, Balboni A, Imposimato I, Battilani M, Gialletti R, Freccero F. Medical management and positive outcome after prolonged recumbency in a case of equine herpesvirus myeloencephalopathy. J Equine Vet Sci 2024; 136:105063. [PMID: 38608970 DOI: 10.1016/j.jevs.2024.105063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2024] [Revised: 03/03/2024] [Accepted: 04/04/2024] [Indexed: 04/14/2024]
Abstract
A 17-year-old mare presenting with acute fever, weakness and bladder dysfunction was diagnosed with equine herpesvirus myeloencephalopathy (EHM). The mare become transiently recumbent, underwent parenteral fluid therapy, plasma infusion, steroidal/nonsteroidal anti-inflammatory drugs (SAID/NSAIDs) and bladder catheterization. After 10 days the mare was hospitalized. Neurological evaluation revealed ataxia and proprioceptive deficits mainly in the hind limbs. The mare was able to stand but unable to rise from recumbency or walk. Secondary complications included Escherichia coli cystitis, corneal ulcers and pressure sores. A full-body support sling was used for 21 days. Medical treatment included systemic antimicrobials, NSAIDs, gradual discontinuation of SAIDs, parenteral fluid therapy and bladder lavage. The mare tested positive for Varicellovirus equidalpha 1 (EHV-1) DNA in nasal swab and blood samples on day 13 and in urine samples on days 13 and 25 after the onset of fever. Neurological signs improved over a period of 34 days and the mare was discharged with mild hind limb weakness/ataxia. Secondary complications resolved within 2 weeks. At the eight-month follow-up, marked improvement in locomotory function had been achieved.
Collapse
Affiliation(s)
- A Mannini
- Department of Veterinary Medical Sciences (DIMEVET), University of Bologna, Via Tolara di Sopra 50, 40064 Ozzano dell'Emilia, Bologna, Italy
| | - N Ellero
- Department of Veterinary Medical Sciences (DIMEVET), University of Bologna, Via Tolara di Sopra 50, 40064 Ozzano dell'Emilia, Bologna, Italy.
| | - L Urbani
- Department of Veterinary Medical Sciences (DIMEVET), University of Bologna, Via Tolara di Sopra 50, 40064 Ozzano dell'Emilia, Bologna, Italy
| | - A Balboni
- Department of Veterinary Medical Sciences (DIMEVET), University of Bologna, Via Tolara di Sopra 50, 40064 Ozzano dell'Emilia, Bologna, Italy
| | - I Imposimato
- Department of Veterinary Medical Sciences (DIMEVET), University of Bologna, Via Tolara di Sopra 50, 40064 Ozzano dell'Emilia, Bologna, Italy
| | - M Battilani
- Department of Veterinary Medical Sciences (DIMEVET), University of Bologna, Via Tolara di Sopra 50, 40064 Ozzano dell'Emilia, Bologna, Italy
| | - R Gialletti
- Department of Veterinary Science, University of Parma, Strada del Taglio 10, 43126 Parma, Italy
| | - F Freccero
- Department of Veterinary Medical Sciences (DIMEVET), University of Bologna, Via Tolara di Sopra 50, 40064 Ozzano dell'Emilia, Bologna, Italy
| |
Collapse
|
9
|
Hassanien RT, Thieulent CJ, Carossino M, Li G, Balasuriya UBR. Modulation of Equid Herpesvirus-1 Replication Dynamics In Vitro Using CRISPR/Cas9-Assisted Genome Editing. Viruses 2024; 16:409. [PMID: 38543774 PMCID: PMC10975850 DOI: 10.3390/v16030409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Revised: 02/29/2024] [Accepted: 03/02/2024] [Indexed: 05/23/2024] Open
Abstract
(1) Background: equid alphaherpesvirus-1 (EHV-1) is a highly contagious viral pathogen prevalent in most horse populations worldwide. Genome-editing technologies such as CRISPR/Cas9 have become powerful tools for precise RNA-guided genome modifications; (2) Methods: we designed single guide RNAs (sgRNA) to target three essential (ORF30, ORF31, and ORF7) and one non-essential (ORF74) EHV-1 genes and determine their effect on viral replication dynamics in vitro; (3) Results: we demonstrated that sgRNAs targeting essential lytic genes reduced EHV-1 replication, whereas those targeting ORF74 had a negligible effect. The sgRNAs targeting ORF30 showed the strongest effect on the suppression of EHV-1 replication, with a reduction in viral genomic copy numbers and infectious progeny virus output. Next-generation sequencing identified variants with deletions in the specific cleavage site of selective sgRNAs. Moreover, we evaluated the combination between different sgRNAs and found that the dual combination of sgRNAs targeting ORF30 and ORF7 significantly suppressed viral replication to lower levels compared to the use of a single sgRNA, suggesting a synergic effect; (4) Conclusion: data demonstrate that sgRNA-guided CRISPR/Cas9 can be used to inhibit EHV-1 replication in vitro, indicating that this programmable technique can be used to develop a novel, safe, and efficacious therapeutic and prophylactic approach against EHV-1.
Collapse
Affiliation(s)
- Rabab T. Hassanien
- Louisiana Animal Disease Diagnostic Laboratory, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA; (R.T.H.); (C.J.T.); (M.C.)
- Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA
- Virology Department, Animal Health Research Institute, Agriculture Research Center (ARC), Dokki, Giza 12618, Egypt
| | - Côme J. Thieulent
- Louisiana Animal Disease Diagnostic Laboratory, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA; (R.T.H.); (C.J.T.); (M.C.)
- Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA
| | - Mariano Carossino
- Louisiana Animal Disease Diagnostic Laboratory, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA; (R.T.H.); (C.J.T.); (M.C.)
- Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA
| | - Ganwu Li
- Department of Veterinary Diagnostics and Production Animal Medicine, Iowa State University, Ames, IA 50011, USA;
| | - Udeni B. R. Balasuriya
- Louisiana Animal Disease Diagnostic Laboratory, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA; (R.T.H.); (C.J.T.); (M.C.)
- Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA
| |
Collapse
|
10
|
Frippiat T, Dams L, Wielick C, Delguste C, Ludwig-Begall LF, Art T, Thiry E. In vitro virucidal activity of nebulized citrate-complexed silver nanoparticles against equine herpesvirus-1 and murine norovirus. Virology 2023; 585:232-239. [PMID: 37406580 DOI: 10.1016/j.virol.2023.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Revised: 05/25/2023] [Accepted: 06/05/2023] [Indexed: 07/07/2023]
Abstract
Viruses can be involved in respiratory disorders in horses, with limited therapeutic options. Citrate-complexed silver nanoparticles (C-AgNP) have shown bactericidal properties after in vitro nebulization. The aim of the present study was to assess the virucidal activity of C-AgNP after in vitro instillation or nebulization on equine herpesvirus-1 (EHV-1) and murine norovirus (MNV), the latter used as surrogate for small non-enveloped viruses. Both viruses were instilled or nebulized with C-AgNP of increasing concentrations, and titres were determined via TCID50 method. We demonstrated efficient inactivation of enveloped EHV-1 following instillation and nebulization of C-AgNP (infectivity losses of ≥ three orders of magnitude). While tenacious MNV was inactivated via 2000 ppm C-AgNP instillation, nebulized C-AgNP did not lead to reduction in MNV titres. Nebulization of C-AgNP may represent a novel virucidal therapeutic approach in horses. Further investigations are needed to assess its safety and effective concentrations for in vivo use.
Collapse
Affiliation(s)
- Thibault Frippiat
- Equine Sports Medicine Centre, Faculty of Veterinary Medicine, University of Liege, Belgium; Sportpaardenarts - Equine Sports Medicine, Laren, the Netherlands.
| | - Lorène Dams
- Veterinary Virology and Animal Viral Diseases, Department of Infectious and Parasitic Diseases, FARAH Research Centre, Faculty of Veterinary Medicine, University of Liege, Belgium
| | - Constance Wielick
- Veterinary Virology and Animal Viral Diseases, Department of Infectious and Parasitic Diseases, FARAH Research Centre, Faculty of Veterinary Medicine, University of Liege, Belgium
| | - Catherine Delguste
- General Services, FARAH Research Centre, Faculty of Veterinary Medicine, University of Liege, Belgium
| | - Louisa F Ludwig-Begall
- Veterinary Virology and Animal Viral Diseases, Department of Infectious and Parasitic Diseases, FARAH Research Centre, Faculty of Veterinary Medicine, University of Liege, Belgium
| | - Tatiana Art
- Equine Sports Medicine Centre, Faculty of Veterinary Medicine, University of Liege, Belgium
| | - Etienne Thiry
- Veterinary Virology and Animal Viral Diseases, Department of Infectious and Parasitic Diseases, FARAH Research Centre, Faculty of Veterinary Medicine, University of Liege, Belgium
| |
Collapse
|
11
|
Black JB, Frampton AR. Anti-inflammatory compounds reduce equine herpesvirus type 1 replication and cell-to-cell spread. Front Vet Sci 2023; 10:1165917. [PMID: 37275614 PMCID: PMC10235532 DOI: 10.3389/fvets.2023.1165917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Accepted: 04/24/2023] [Indexed: 06/07/2023] Open
Abstract
Equine herpesvirus type 1 (EHV-1) is a highly transmissible pathogen that leads to a variety of clinical disease outcomes in infected horses. A major sequela that can occur after an EHV-1 infection is a neurological disease termed equine herpesvirus myeloencephalopathy (EHM). Clinical manifestations of EHM include fever, ataxia, incontinence, and partial to full paralysis, which may ultimately lead to the euthanization of the infected horse. To develop an effective treatment strategy for EHM, it is critical that the specific virus-host interactions that lead to EHM be investigated so that safe and effective therapeutic interventions can be developed and delivered. In this study, we examined the ability of four non-steroidal anti-inflammatory drugs (NSAIDs), a steroidal anti-inflammatory drug (dexamethasone), a Rho-kinase (ROCK) inhibitor, and a JAK/STAT inhibitor (AG490) to reduce EHV-1 virus yields and cell-to-cell spread. We show that the NSAID, flunixin meglumine (FM), and the JAK/STAT inhibitor, AG490, significantly reduced virus yields in endothelial and epithelial cell lines, and this inhibition was similar for two neurologic and two non-neurologic EHV-1 strains. In addition to reducing virus yields, AG490 and FM also significantly reduced the ability of EHV-1 to spread laterally from cell to cell.
Collapse
|
12
|
Barbosa JD, Lins ADMC, Bomjardim HDA, Silveira NDSES, Barbosa CC, Beuttemmuller EA, Brito MF, Salvarani FM. Equine Herpesvirus Type 1 Myeloencephalitis in the Brazilian Amazon. Animals (Basel) 2022; 13:ani13010059. [PMID: 36611668 PMCID: PMC9817990 DOI: 10.3390/ani13010059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2022] [Revised: 11/21/2022] [Accepted: 11/26/2022] [Indexed: 12/28/2022] Open
Abstract
An investigative and epidemiological study was carried out for equine herpesvirus type 1 (HVE-1) in 10 outbreaks of neurological disease from different farms in the state of Pará, Brazil. 25 horses were studied: six male and 19 females, aged between one and 13 years. A necropsy of six horses was performed, and the others recovered either with or without treatment (T1-vitamin B1 + dexamentasone; T2-vitamin B1 + flunixim meglumine). Animals that received treatment recovered after eight days. The main clinical signs observed were motor incoordination, progressive paresis, thoracic and/or pelvic limbs abducted after induction of clinical examination, knuckling of the hind fetlocks, sagging and swaying of the hindquarters while standing or walking and paresis. All animals were positive: 88% (22/25) in nested PCR and 72% (18/25) in serum neutralization (including three negatives in serology). Focal brownish areas compatible with hemorrhage were found in the white and gray matter of the spinal cord of two animals. On histological analysis, there were perivasculitis and neutrophilic vasculitis in the gray matter of the spinal cord and brain. Based on the evidence, this work proves the circulation of HVE-1 in the Amazon biome, mainly in the state of Pará, Brazil.
Collapse
Affiliation(s)
- José Diomedes Barbosa
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal 68740-970, PA, Brazil
| | | | - Henrique dos Anjos Bomjardim
- Instituto de Estudos do Trópico Úmido (IETU), Universidade Federal do Sul e Sudeste do Pará (Unifesspa), Xinguara 68557-335, PA, Brazil
| | | | - Camila Cordeiro Barbosa
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal 68740-970, PA, Brazil
| | - Edsel Alves Beuttemmuller
- Centro de Ciências Agrárias, Universidade Estadual de Londrina (UEL), Londrina 86057-070, PR, Brazil
| | - Marilene Farias Brito
- Departamento de Epidemiologia e Saúde Pública (DESP), Instituto de Veterinária (IV), Universidade Federal Rural do Rio de Janeiro (UFRRJ), Seropédica 23890-000, RJ, Brazil
| | - Felipe Masiero Salvarani
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal 68740-970, PA, Brazil
- Correspondence:
| |
Collapse
|
13
|
Klouth E, Zablotski Y, Petersen JL, de Bruijn M, Gröndahl G, Müller S, Goehring LS. Epidemiological Aspects of Equid Herpesvirus-Associated Myeloencephalopathy (EHM) Outbreaks. Viruses 2022; 14:v14112576. [PMID: 36423188 PMCID: PMC9695031 DOI: 10.3390/v14112576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2022] [Accepted: 11/15/2022] [Indexed: 11/23/2022] Open
Abstract
Equid Herpesvirus Myeloencephalopathy (EHM) is a multifactorial disease following an EHV-1 infection in Equidae. We investigated a total of 589 horses on 13 premises in Europe in search of risk factors for the development of EHM. We found that fever (p < 0.001), increasing age (p = 0.032), and female sex (p = 0.042) were risk factors for EHM in a logistic mixed model. Some breeds had a decreased risk to develop EHM compared to others (Shetland and Welsh ponies; p = 0.017; p = 0.031), and fewer EHV-1-vaccinated horses were affected by EHM compared to unvaccinated horses (p = 0.02). Data evaluation was complex due to high variability between outbreaks with regards to construction and environment; viral characteristics and the virus's transmissibility were affected by operational management. This study confirms earlier suspected host-specific risk factors, and our data support the benefit of high vaccine coverage at high-traffic boarding facilities.
Collapse
Affiliation(s)
- Eva Klouth
- Center for Clinical Veterinary Medicine, Faculty of Veterinary Medicine, Ludwig-Maximilians University, 80539 Munich, Germany
| | - Yury Zablotski
- Center for Clinical Veterinary Medicine, Faculty of Veterinary Medicine, Ludwig-Maximilians University, 80539 Munich, Germany
| | - Jessica L. Petersen
- Department of Animal Science, University of Nebraska, Lincoln, NE 68588, USA
| | - Marco de Bruijn
- Wolvega Equine Hospital, 8474 EA Oldeholtpade, The Netherlands
| | | | - Susanne Müller
- Baden-Wuerttemberg Animal Health Services, 70736 Fellbach, Germany
| | - Lutz S. Goehring
- M.H. Gluck Equine Research Center, College of Agriculture, Food and the Environment, University of Kentucky, Lexington, KY 40506, USA
- Correspondence:
| |
Collapse
|
14
|
Sosa-Higareda M, Yazdi Z, Littman EM, Quijano Cardé EM, Yun S, Soto E. Efficacy of a multidose acyclovir protocol against cyprinid herpesvirus 3 infection in koi (Cyprinus carpio). Am J Vet Res 2022; 83:ajvr.22.02.0030. [DOI: 10.2460/ajvr.22.02.0030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Abstract
OBJECTIVE
To evaluate the effect of a multidose acyclovir protocol on koi herpesvirus (KHV) viral load and mortality in a cohabitation challenge.
ANIMALS
180 koi fish.
PROCEDURES
Forty fish (shedders) were immersed in a 0.5 KHV plaque-forming units/mL static bath for 8 hours. Mock shedders were treated similarly but exposed to cell culture media. KHV shedders were then transferred into 8 tanks (5 shedders per tank) containing 10 naïve fish (cohabitants) each. Fish in the acyclovir group (AT) received a 10 mg/kg acyclovir intracoelomic injection 1, 3, and 6 days after the first confirmed KHV mortality. Positive controls (PC) were treated similarly but received sterile saline injections. Negative controls (NC) were exposed to mock shedders. Morbidity and mortality were evaluated daily for 50 days post-challenge. Quantitative PCR was used to determine viral load in the gill biopsies of shedders and cohabitants collected at days 19 (T1), 22 (T2), 25 (T3), 34 (T4), and 50 (T5) post-challenge.
RESULTS
Survival curves analyzed by the Gehan-Breslow-Wilcoxon method revealed a delayed onset of mortalities and a significantly lower KHV load at T2 and T3 detected in AT cohabitant fish (P = .042) compared to PC group. However, there were no significant differences in overall mortality or viral loads at T5.
CLINICAL RELEVANCE
The acyclovir protocol used in this study did not control viral infection or mortality at the end of the 50-day trial. Shorter intervals between injections could improve outcomes, but the additional stress inflicted by handling should be considered. Exploring other therapeutic alternatives and doses is warranted.
Collapse
Affiliation(s)
- Mariana Sosa-Higareda
- William T. Pritchard Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, CA
| | - Zeinab Yazdi
- Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA
| | - Eric M. Littman
- William T. Pritchard Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, CA
- Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA
| | - Eva Marie Quijano Cardé
- Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA
| | - Susan Yun
- Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA
| | - Esteban Soto
- Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA
| |
Collapse
|
15
|
Oral Administration of Valganciclovir Reduces Clinical Signs, Virus Shedding and Cell-Associated Viremia in Ponies Experimentally Infected with the Equid Herpesvirus-1 C2254 Variant. Pathogens 2022; 11:pathogens11050539. [PMID: 35631060 PMCID: PMC9148010 DOI: 10.3390/pathogens11050539] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Revised: 04/27/2022] [Accepted: 04/30/2022] [Indexed: 12/10/2022] Open
Abstract
Equid alphaherpesvirus-1 (EHV-1) is one of the main pathogens in horses, responsible for respiratory diseases, ocular diseases, abortions, neonatal foal death and neurological complications such as equine herpesvirus myeloencephalopathy (EHM). Current vaccines reduce the excretion and dissemination of the virus and, therefore, the extent of an epizooty. While their efficacy against EHV-1-induced abortion in pregnant mares and the decreased occurrence of an abortion storm in the field have been reported, their potential efficacy against the neurological form of disease remains undocumented. No antiviral treatment against EHV-1 is marketed and recommended to date. This study aimed to measure the protection induced by valganciclovir (VGCV), the prodrug of ganciclovir, in Welsh mountain ponies experimentally infected with an EHV-1 ORF30-C2254 strain. Four ponies were administered VGCV immediately prior to experimental EHV-1 infection, while another four ponies received a placebo. The treatment consisted in 6.5 mg/kg body weight of valganciclovir administered orally three times the first day and twice daily for 13 days. Clinical signs of disease, virus shedding and viraemia were measured for up to 3 weeks. The severity of the cumulative clinical score was significantly reduced in the treated group when compared with the control group. Shedding of infectious EHV-1 was significantly reduced in the treated group when compared with the control group between Day + 1 (D + 1) and D + 12. Viraemia was significantly reduced in the treated group when compared with the control group. Seroconversion was measured in all the ponies included in the study, irrespective of the treatment received. Oral administration of valganciclovir induced no noticeable side effect but reduced clinical signs of disease, infectious virus shedding and viraemia in ponies experimentally infected with the EHV-1 C2254 variant.
Collapse
|
16
|
Pharmacokinetics and analytical determination of acyclovir in Asian elephant calves ( Elephas maximus). Vet Anim Sci 2022; 15:100227. [PMID: 35024493 PMCID: PMC8724961 DOI: 10.1016/j.vas.2021.100227] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2021] [Revised: 12/09/2021] [Accepted: 12/22/2021] [Indexed: 12/04/2022] Open
Abstract
Pharmacokinetic and bioavailability data of acyclovir following intravenous and oral administration are reported for Asian elephant calves. Data represent the first comprehensive LC-MS/MS analysis of plasma acyclovir concentrations after i.v. and oral administration in elephants.
A therapeutic regimen that includes antiviral drugs is critical for the survival of Asian elephant (Elephas maximus) calves infected with elephant endotheliotropic herpesvirus hemorrhagic disease (EEHV-HD), with acyclovir showing considerable promise. The purpose of this study was to determine the pharmacokinetics and bioavailability of acyclovir following intravenous (IV) and oral (PO) administration in Asian elephants. A single dose of acyclovir (15 mg/kg, IV or 45 mg/kg, PO) was administered to four healthy elephant calves, with a minimum 2-week washout period between treatments. Serial plasma samples were collected after each injection for acyclovir analysis using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) technique. Maximum plasma acyclovir concentrations were 27.02 ± 6.79 µg/mL at 0.94 ± 0.31 h after IV administration, and 1.45 ± 0.20 µg/mL at 3.00 ± 0.70 h after PO administration. The half-life of the elimination phase (T1/2) was 5.84 ± 0.74 and 8.74 ± 2.47 h after IV and PO administration, respectively. After IV administration, acyclovir concentrations were higher than the half-maximal inhibitory concentration (IC50) of those found for herpes simplex virus (HSV) 1 and 2 in humans, and equid alpha herpesvirus-1 (EHV-1) for at least 12 h. By contrast, the bioavailability of oral administration was low, only 6.03 ± 0.87%, so higher doses by that route likely are needed to be effective. Due to the high concentration of plasma acyclovir after IV administration, the dose may need to be adjusted to prevent any negative side effects.
Collapse
Key Words
- %CV, Mean precision
- AUC0-inf, Total area under the plasma concentration-time curve from time zero to infinity
- AUC0-t, Total area under the plasma concentration-time curve from time 0–48h
- Acyclovir
- Asian elephant
- Bioavailability
- Cl, Total clearance
- Cmax, Peak plasma concentration
- EEHV, Elephantendotheliotropic herpesviruses
- EEHV-HD, Elephant endotheliotropic herpesvirus hemorrhagic disease
- EHV, Equid alphaherpesvirus
- Elephant endotheliotropic herpesvirus (EEHV)
- F, Bioavailability
- HSV, Herpes simplex virus
- IV, Intravenous administration
- Kel, Elimination rate constant
- LC-MS/MS, Liquid chromatography-tandem mass spectrometry
- LLOQ, Lower limit of quantitation
- MAT, Mean absorption time
- MRM, Multiple reaction monitoring
- MRT, Mean residence time
- PO, Oral administration
- Pharmacokinetics
- QC, Quality control
- S/N, Signal to noise ratio
- T1/2, Elimination half-life
- Tmax, Time to reach peak plasma
- Vd(ss), Steady-state volume of distribution
- m/z, Mass-to-charge ratio
- r2, Coefficients of determination
Collapse
|
17
|
Nielsen SS, Alvarez J, Bicout DJ, Calistri P, Canali E, Drewe JA, Garin‐Bastuji B, Gonzales Rojas JL, Gortázar C, Herskin M, Michel V, Miranda Chueca MÁ, Roberts HC, Padalino B, Pasquali P, Spoolder H, Ståhl K, Calvo AV, Viltrop A, Winckler C, Carvelli A, Paillot R, Broglia A, Kohnle L, Baldinelli F, Van der Stede Y. Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): infection with Equine Herpesvirus-1. EFSA J 2022; 20:e07036. [PMID: 35035581 PMCID: PMC8753587 DOI: 10.2903/j.efsa.2022.7036] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Equine Herpesvirus-1 infection has been assessed according to the criteria of the Animal Health Law (AHL), in particular criteria of: Article 7 on disease profile and impacts, Article 5 on the eligibility of the disease to be listed, Article 9 for the categorisation of the disease according to disease prevention and control measures as in Annex IV and Article 8 on the list of animal species related to Equine Herpesvirus-1 infection. The assessment has been performed following a methodology composed of information collection and compilation, and expert judgement on each criterion at individual and collective level. The outcome is the median of the probability ranges provided by the experts, which indicates whether the criterion is fulfilled (66-100%) or not (0-33%), or whether there is uncertainty about fulfilment (33-66%). For the questions where no consensus was reached, the different supporting views are reported. According to the assessment performed, Equine Herpesvirus-1 infection can be considered eligible to be listed for Union intervention according to Article 5 of the Animal Health Law with 33-90% certainty. According to the criteria as in Annex IV of the AHL related to Article 9 of the AHL for the categorisation of diseases according to the level of prevention and control, it was assessed with less than 1% certainty that EHV-1 fulfils the criteria as in Section 1 (category A), 1-5% for the criteria as in Section 2 (category B), 10-66% for the criteria as in Section 3 (category C), 66-90% for the criteria as in Section 4 (category D) and 33-90% for the criteria as in Section 5 (category E). The animal species to be listed for EHV-1 infection according to Article 8(3) criteria are the species belonging to the families of Equidae, Bovidae, Camelidae, Caviidae, Cervidae, Cricetidae, Felidae, Giraffidae, Leporidae, Muridae, Rhinocerontidae, Tapiridae and Ursidae.
Collapse
|
18
|
Easton-Jones C. Recent advancements in our understanding of equid gammaherpesvirus infections. Equine Vet J 2021; 54:11-23. [PMID: 34519074 DOI: 10.1111/evj.13512] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Revised: 06/18/2021] [Accepted: 09/03/2021] [Indexed: 12/19/2022]
Abstract
Equid gammaherpesviruses are ubiquitous and widespread in the equine population. Despite their frequent detection, their contribution to immune system modulation and the pathogenesis of several diseases remains unclear. Genetic variability and the combination of equid gammaherpesvirus strains a horse is infected with might be clinically significant. Initial gammaherpesvirus infection occurs in foals peripartum with latency then established in peripheral blood mononuclear cells. A novel EHV-5 study suggests that following inhalation equid gammaherpesviruses might obtain direct access to T and B lymphocytes via the tonsillar crypts to establish latency. EHV-5 is associated with equine multinodular pulmonary fibrosis, however, unlike with EHV-2 there is currently minimal evidence for its role in milder cases of respiratory disease and poor performance. Transmission is presumed to be via the upper respiratory tract with periodic reactivation of the latent virus in adult horses. Stress of transport has been identified as a risk factor for reactivation and shedding of equine gammaherpesviruses. There is currently a lack of evidence for the effectiveness of antiviral drugs in the treatment of equine gammaherpesvirus infections.
Collapse
|
19
|
New Insights into the Management of an EHV-1 (Equine Hospital) Outbreak. Viruses 2021; 13:v13081429. [PMID: 34452295 PMCID: PMC8402800 DOI: 10.3390/v13081429] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Revised: 07/13/2021] [Accepted: 07/16/2021] [Indexed: 11/16/2022] Open
Abstract
In May 2018, Wolvega Equine Hospital (WEH) experienced an EHV-1 outbreak. This outbreak caused significant economic losses and negative publicity for the hospital. How should hospitals prepare themselves for these outbreaks and prevent shedding of the virus on multiple neighboring premises? The hospital transformed most of its activities into mobile practice and the entire infected hospital population was moved to a separate remote location. The hospital was cleaned and disinfected according to the latest recommendations before reopening. Four neighboring professional equine businesses and three privately owned premises were affected by the spread of the virus from the hospital population and initiated quarantine restrictions. Equine hospitals should prepare themselves for EHV-1 outbreaks as the intake of the virus cannot be prevented. A management protocol should include public information protocols, swift client information and quarantine measures that ensure quick containment of the outbreak. Timely reopening of the hospital can be achieved by rehousing the contaminated population. It should also include good regulations with clients and a properly carried out release protocol. Equine sports organizations should establish sufficient vaccination coverage in order to decrease the frequency of EHV-1 outbreaks.
Collapse
|
20
|
EQUID ALPHAHERPESVIRUS 9 OUTBREAK ASSOCIATED WITH MORTALITY IN A GROUP OF GREVY'S ZEBRA ( EQUUS GREVYI) HOUSED IN A MIXED-SPECIES EXHIBIT. J Zoo Wildl Med 2021; 52:774-778. [PMID: 34130425 DOI: 10.1638/2019-0109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/26/2021] [Indexed: 11/21/2022] Open
Abstract
A herd of seven captive-born Grevy's zebras (Equus grevyi) experienced an outbreak of nasal discharge and sneezing. Clinical signs, including lethargy and anorexia, were severe and acute in three animals, including a 16-mo-old male that died within 48 h. Treatment of two severely affected zebras included valacyclovir (40 mg/kg PO), meloxicam (0.6 mg/kg IM/PO), and cefquinome (2.5 mg/kg IM q48h). An adult female improved rapidly, and clinical signs resolved within 48 h of treatment. Administration of valacyclovir pellets was very complicated in a 2-mo-old female, and death occurred within 48 h. Histologic examination of the two individuals that died revealed severe fibrinonecrotic interstitial pneumonia with prominent hyaline membranes and type II pneumocyte hyperplasia. Additionally, the 16-mo-old male presented systemic endothelial activation with vascular thrombosis and necrosis and mild nonsuppurative meningoencephalitis. Herpesviral DNA was detected in the lungs of both individuals by nested polymerase chain reaction. The nucleic acid sequence of the amplicons showed 100% similarity with previously published equid alphaherpesvirus 9 sequences. Three additional animals developed mild nasal discharge only and recovered spontaneously. The zebras shared housing facilities with other species, including white rhinoceros (Ceratotherium simum), reticulated giraffe (Giraffa camelopardalis reticulata), and several antelope species. None of these animals showed clinical signs. Additionally, nasal swabs and whole blood samples were collected from cohoused white rhinoceroses (n = 3) and springboks (Antidorcas marsupialis, n = 3) as well as nasal swabs from cohoused reticulated giraffes (n = 4). Nucleic acid sequence from equid herpesviruses was not detected in any of these samples. The source of the infection in the zebras remains unclear.
Collapse
|
21
|
Pusterla N, Barnum S, Miller J, Varnell S, Dallap-Schaer B, Aceto H, Simeone A. Investigation of an EHV-1 Outbreak in the United States Caused by a New H 752 Genotype. Pathogens 2021; 10:747. [PMID: 34199153 PMCID: PMC8231618 DOI: 10.3390/pathogens10060747] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 06/07/2021] [Accepted: 06/10/2021] [Indexed: 12/21/2022] Open
Abstract
Here we report on an EHV-1 outbreak investigation caused by a novel genotype H752 (histidine in amino acid position 752 of the ORF 30 gene). The outbreak involved 31 performance horses. Horses were monitored over a period of 35 days for clinical signs, therapeutic outcome and qPCR results of EHV-1 in blood and nasal secretions. The morbidity of the EHV-1 outbreak was 84% with 26 clinically infected horses displaying fever and less frequently anorexia and distal limb edema. Four horses showed mild transient neurological deficits. Clinically diseased horses experienced high viral load of EHV-1 in blood and/or nasal secretions via qPCR, while subclinically infected horses had detectable EHV-1 mainly in nasal secretions. The majority of infected horses showed a rise in antibody titers to EHV-1 during the outbreak. All 31 horses were treated with valacyclovir, while clinically infected horses further received flunixin meglumine and sodium heparin. This investigation highlights various relevant aspects of an EHV-1 outbreak caused by a new H752 genotype: (i) importance of early detection of EHV-1 infection; (ii) diagnostic challenge to assess H752 genotype; (iii) apparent benefit of valacyclovir use in the early stage of the outbreak; and (iv) weekly testing of blood and nasal secretions by qPCR in order to monitor individual infection status and lift quarantine.
Collapse
Affiliation(s)
- Nicola Pusterla
- Department of Veterinary Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA 95616, USA;
| | - Samantha Barnum
- Department of Veterinary Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA 95616, USA;
| | - Julia Miller
- Alliance Equine Health Care, Glenmoore, PA 19343, USA; (J.M.); (S.V.)
| | - Sarah Varnell
- Alliance Equine Health Care, Glenmoore, PA 19343, USA; (J.M.); (S.V.)
| | - Barbara Dallap-Schaer
- Department of Clinical Studies, New Bolton Center, University of Pennsylvania, Kennett Square, PA 19348, USA; (B.D.-S.); (H.A.)
| | - Helen Aceto
- Department of Clinical Studies, New Bolton Center, University of Pennsylvania, Kennett Square, PA 19348, USA; (B.D.-S.); (H.A.)
| | - Aliza Simeone
- Pennsylvania Department of Agriculture, Bureau of Animal Health, Collegeville, PA 17110, USA;
| |
Collapse
|
22
|
Zarski LM, Giessler KS, Jacob SI, Weber PSD, McCauley AG, Lee Y, Soboll Hussey G. Identification of Host Factors Associated with the Development of Equine Herpesvirus Myeloencephalopathy by Transcriptomic Analysis of Peripheral Blood Mononuclear Cells from Horses. Viruses 2021; 13:v13030356. [PMID: 33668216 PMCID: PMC7995974 DOI: 10.3390/v13030356] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Revised: 02/18/2021] [Accepted: 02/19/2021] [Indexed: 12/13/2022] Open
Abstract
Equine herpesvirus-1 is the cause of respiratory disease, abortion, and equine herpesvirus myeloencephalopathy (EHM) in horses worldwide. EHM affects as many as 14% of infected horses and a cell-associated viremia is thought to be central for EHM pathogenesis. While EHM is infrequent in younger horses, up to 70% of aged horses develop EHM. The aging immune system likely contributes to EHM pathogenesis; however, little is known about the host factors associated with clinical EHM. Here, we used the “old mare model” to induce EHM following EHV-1 infection. Peripheral blood mononuclear cells (PBMCs) of horses prior to infection and during viremia were collected and RNA sequencing with differential gene expression was used to compare the transcriptome of horses that did (EHM group) and did not (non-EHM group) develop clinical EHM. Interestingly, horses exhibiting EHM did not show respiratory disease, while non-EHM horses showed significant respiratory disease starting on day 2 post infection. Multiple immune pathways differed in EHM horses in response to EHV-1. These included an upregulation of IL-6 gene expression, a dysregulation of T-cell activation through AP-1 and responses skewed towards a T-helper 2 phenotype. Further, a dysregulation of coagulation and an upregulation of elements in the progesterone response were observed in EHM horses.
Collapse
Affiliation(s)
- Lila M. Zarski
- Department of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, MI 48824, USA; (L.M.Z.); (K.S.G.); (S.I.J.); (A.G.M.); (Y.L.)
| | - Kim S. Giessler
- Department of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, MI 48824, USA; (L.M.Z.); (K.S.G.); (S.I.J.); (A.G.M.); (Y.L.)
| | - Sarah I. Jacob
- Department of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, MI 48824, USA; (L.M.Z.); (K.S.G.); (S.I.J.); (A.G.M.); (Y.L.)
| | - Patty Sue D. Weber
- Department of Large Animal Clinical Sciences, Michigan State University, East Lansing, MI 48824, USA;
| | - Allison G. McCauley
- Department of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, MI 48824, USA; (L.M.Z.); (K.S.G.); (S.I.J.); (A.G.M.); (Y.L.)
| | - Yao Lee
- Department of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, MI 48824, USA; (L.M.Z.); (K.S.G.); (S.I.J.); (A.G.M.); (Y.L.)
| | - Gisela Soboll Hussey
- Department of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, MI 48824, USA; (L.M.Z.); (K.S.G.); (S.I.J.); (A.G.M.); (Y.L.)
- Correspondence:
| |
Collapse
|
23
|
Stokol T, Soboll Hussey G. Editorial: Current Research in Equid Herpesvirus Type-1 (EHV-1). Front Vet Sci 2020; 6:492. [PMID: 31998768 PMCID: PMC6965053 DOI: 10.3389/fvets.2019.00492] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2019] [Accepted: 12/12/2019] [Indexed: 01/20/2023] Open
Affiliation(s)
- Tracy Stokol
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States
| | - Gisela Soboll Hussey
- Department of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, East Lansing, MI, United States
| |
Collapse
|
24
|
Lechmann J, Schoster A, Ernstberger M, Fouché N, Fraefel C, Bachofen C. A novel PCR protocol for detection and differentiation of neuropathogenic and non-neuropathogenic equid alphaherpesvirus 1. J Vet Diagn Invest 2019; 31:696-703. [PMID: 31477001 DOI: 10.1177/1040638719871975] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Equid alphaherpesvirus 1 (EHV-1) infections can have a major impact on the horse industry and equine welfare by causing abortion or respiratory or neurologic disease. A single nucleotide polymorphism (A2254→G2254) in open reading frame (ORF) 30, encoding the catalytic subunit of the DNA polymerase, has been shown to be a strong predictive marker for neuropathogenicity. Given that a previously established real-time PCR (rtPCR) protocol yielded unsatisfactory results concerning determination of the EHV-1 genotype, we developed and evaluated a new conventional PCR protocol enabling identification of the genotype by sequencing and restriction enzyme analysis (REA). Thirty samples from horses with signs typical for EHV-1 infection were tested by rtPCR and our new conventional PCR. The results showed that compared to rtPCR, the conventional PCR protocol combined with sequencing and REA was more reliable concerning unambiguous determination of the EHV-1 genotype. Results of our new assay confirmed previous findings, according to which the non-neuropathogenic genotype A2254 is predominantly found in animals with fever, respiratory signs, and abortions or perinatal mortality, whereas the neuropathogenic genotype G2254 is primarily detected in animals suffering from neurologic disease. In some samples, results pointed towards coinfection with both genotypes. Further studies are required in order to elucidate the significance of infections with genotype A2254 and G2254 in neurologic and non-neurologic cases, respectively.
Collapse
Affiliation(s)
- Julia Lechmann
- Institute of Virology (Lechmann, Fraefel, Bachofen), Equine Department, Clinic for Equine Internal Medicine (Schoster), Department of Farm Animals, Division of Herd Medicine and Outpatient Clinic (Ernstberger), Vetsuisse Faculty, University of Zurich, Zurich Switzerland.,Swiss Institute of Equine Medicine ISME, Department of Clinical Veterinary Medicine, Vetsuisse Faculty, University of Bern, and Agroscope, Bern, Switzerland (Fouché)
| | - Angelika Schoster
- Institute of Virology (Lechmann, Fraefel, Bachofen), Equine Department, Clinic for Equine Internal Medicine (Schoster), Department of Farm Animals, Division of Herd Medicine and Outpatient Clinic (Ernstberger), Vetsuisse Faculty, University of Zurich, Zurich Switzerland.,Swiss Institute of Equine Medicine ISME, Department of Clinical Veterinary Medicine, Vetsuisse Faculty, University of Bern, and Agroscope, Bern, Switzerland (Fouché)
| | - Martina Ernstberger
- Institute of Virology (Lechmann, Fraefel, Bachofen), Equine Department, Clinic for Equine Internal Medicine (Schoster), Department of Farm Animals, Division of Herd Medicine and Outpatient Clinic (Ernstberger), Vetsuisse Faculty, University of Zurich, Zurich Switzerland.,Swiss Institute of Equine Medicine ISME, Department of Clinical Veterinary Medicine, Vetsuisse Faculty, University of Bern, and Agroscope, Bern, Switzerland (Fouché)
| | - Nathalie Fouché
- Institute of Virology (Lechmann, Fraefel, Bachofen), Equine Department, Clinic for Equine Internal Medicine (Schoster), Department of Farm Animals, Division of Herd Medicine and Outpatient Clinic (Ernstberger), Vetsuisse Faculty, University of Zurich, Zurich Switzerland.,Swiss Institute of Equine Medicine ISME, Department of Clinical Veterinary Medicine, Vetsuisse Faculty, University of Bern, and Agroscope, Bern, Switzerland (Fouché)
| | - Cornel Fraefel
- Institute of Virology (Lechmann, Fraefel, Bachofen), Equine Department, Clinic for Equine Internal Medicine (Schoster), Department of Farm Animals, Division of Herd Medicine and Outpatient Clinic (Ernstberger), Vetsuisse Faculty, University of Zurich, Zurich Switzerland.,Swiss Institute of Equine Medicine ISME, Department of Clinical Veterinary Medicine, Vetsuisse Faculty, University of Bern, and Agroscope, Bern, Switzerland (Fouché)
| | - Claudia Bachofen
- Institute of Virology (Lechmann, Fraefel, Bachofen), Equine Department, Clinic for Equine Internal Medicine (Schoster), Department of Farm Animals, Division of Herd Medicine and Outpatient Clinic (Ernstberger), Vetsuisse Faculty, University of Zurich, Zurich Switzerland.,Swiss Institute of Equine Medicine ISME, Department of Clinical Veterinary Medicine, Vetsuisse Faculty, University of Bern, and Agroscope, Bern, Switzerland (Fouché)
| |
Collapse
|
25
|
Oladunni FS, Horohov DW, Chambers TM. EHV-1: A Constant Threat to the Horse Industry. Front Microbiol 2019; 10:2668. [PMID: 31849857 PMCID: PMC6901505 DOI: 10.3389/fmicb.2019.02668] [Citation(s) in RCA: 51] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2019] [Accepted: 11/01/2019] [Indexed: 12/17/2022] Open
Abstract
Equine herpesvirus-1 (EHV-1) is one of the most important and prevalent viral pathogens of horses and a major threat to the equine industry throughout most of the world. EHV-1 primarily causes respiratory disease but viral spread to distant organs enables the development of more severe sequelae; abortion and neurologic disease. The virus can also undergo latency during which viral genes are minimally expressed, and reactivate to produce lytic infection at any time. Recently, there has been a trend of increasing numbers of outbreaks of a devastating form of EHV-1, equine herpesviral myeloencephalopathy. This review presents detailed information on EHV-1, from the discovery of the virus to latest developments on treatment and control of the diseases it causes. We also provide updates on recent EHV-1 research with particular emphasis on viral biology which enables pathogenesis in the natural host. The information presented herein will be useful in understanding EHV-1 and formulating policies that would help limit the spread of EHV-1 within horse populations.
Collapse
Affiliation(s)
- Fatai S. Oladunni
- Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, KY, United States
- Department of Veterinary Microbiology, University of Ilorin, Ilorin, Nigeria
| | - David W. Horohov
- Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, KY, United States
| | - Thomas M. Chambers
- Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, KY, United States
| |
Collapse
|
26
|
Easton‐Jones CA, Cissell DD, Mohr FC, Chigerwe M, Pusterla N. Prognostic indicators and long‐term survival in 14 horses with equine multinodular pulmonary fibrosis. EQUINE VET EDUC 2019. [DOI: 10.1111/eve.13204] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Affiliation(s)
| | - D. D. Cissell
- Surgical and Radiological Sciences DavisCaliforniaUSA
| | - F. C. Mohr
- Pathology, Microbiology and Immunology School of Veterinary Medicine University of California Davis California USA
| | - M. Chigerwe
- Departments of Medicine and Epidemiology DavisCaliforniaUSA
| | - N. Pusterla
- Departments of Medicine and Epidemiology DavisCaliforniaUSA
| |
Collapse
|
27
|
Lanave G, Lucente MS, Siciliano P, Zizzadoro C, Trerotoli P, Martella V, Buonavoglia C, Tempesta M, Camero M. Antiviral activity of PHA767491 on Caprine alphaherpesvirus 1 in vitro. Res Vet Sci 2019; 126:113-117. [PMID: 31445397 DOI: 10.1016/j.rvsc.2019.08.019] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Revised: 08/01/2019] [Accepted: 08/12/2019] [Indexed: 12/16/2022]
Abstract
Caprine alphaherpesvirus 1 (CpHV-1) induces genital lesions in its natural host similar to those caused by Human alphaherpesvirus 2 (HHV-2), commonly named herpes simplex virus 2 (HSV-2) in human patients. CpHV-1 infection in goats could represent a useful homologous animal model for the study of HSV-2 infection, chiefly for the assessment of antiviral drugs in in vivo studies. PHA767491 is a potent inhibitor of HSV-1 and HSV-2, being able to limit replication of HHVs both in vitro and in the mouse model. In the present study the antiviral efficacy of PHA767491 against CpHV-1 was evaluated in vitro in MDBK cells. PHA767491 inhibited significantly CpHV-1 replication in a dose-dependent fashion by up to 2.50 log10 TCID50/50 μl and was able to decrease viral DNA by nearly 8 log10. These findings confirm that PHA767491 is highly effective not only against simplexviruses (HSV-1 and HSV-2), but also against the varicellovirus CpHV-1. Experiments will be necessary to assess whether PHA767491 is suitable for treatment of vaginal lesions in CpHV-1-goat model. This could provide hints for the therapy of genital alphaherpesvirus infections in humans.
Collapse
Affiliation(s)
- Gianvito Lanave
- Department of Veterinary Medicine, University of Bari, Valenzano, Bari, Italy
| | - Maria S Lucente
- Department of Veterinary Medicine, University of Bari, Valenzano, Bari, Italy
| | | | - Claudia Zizzadoro
- Department of Veterinary Medicine, University of Bari, Valenzano, Bari, Italy
| | - Paolo Trerotoli
- Department of Biomedical Science and Human Oncology, University of Bari, Medical School, Bari, Italy
| | - Vito Martella
- Department of Veterinary Medicine, University of Bari, Valenzano, Bari, Italy
| | - Canio Buonavoglia
- Department of Veterinary Medicine, University of Bari, Valenzano, Bari, Italy
| | - Maria Tempesta
- Department of Veterinary Medicine, University of Bari, Valenzano, Bari, Italy
| | - Michele Camero
- Department of Veterinary Medicine, University of Bari, Valenzano, Bari, Italy.
| |
Collapse
|
28
|
Troszok A, Kolek L, Szczygieł J, Wawrzeczko J, Borzym E, Reichert M, Kamińska T, Ostrowski T, Jurecka P, Adamek M, Rakus K, Irnazarow I. Acyclovir inhibits Cyprinid herpesvirus 3 multiplication in vitro. JOURNAL OF FISH DISEASES 2018; 41:1709-1718. [PMID: 30144085 DOI: 10.1111/jfd.12880] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Revised: 07/04/2018] [Accepted: 07/04/2018] [Indexed: 06/08/2023]
Abstract
Cyprinid herpesvirus 3 (CyHV-3), also known as koi herpesvirus (KHV), is an aetiological agent of a virulent and lethal disease in common and koi carp. In this study, we examined in vitro the anti-CyHV-3 activity of acyclovir (ACV), nucleoside analogue commonly used against human herpesviruses, as well as acyclovir monophospate (ACV-MP). The cytotoxicity of the ACV and the ACV-MP for two common carp cell lines, CCB (Common carp brain) and KF1 (Koi carp fin 1), was determined by means of MTT and crystal violet assays. In subsequent studies, the concentration of 66.67 μM was applied. The ACV and the ACV-MP (66.67 μM) inhibited a cytopathic effect (CPE) induced by the CyHV-3 virus in the CCB (ACV by 66%, ACV-MP by 58%) and the KF1 (ACV by 25%, ACV-MP by 37%). The viral load measured by the means of TaqMan qPCR was reduced in a range of 67%-93% depending on the analogue, the cell line and the time of incubation. The expression of viral genes (ORF149, ORF3, ORF134 and ORF78) in CCB cells infected with the CyHV-3 was strongly downregulated within the range of 78%-91%. In summary, both the ACV and the ACV-MP can inhibit CyHV-3 replication in vitro.
Collapse
Affiliation(s)
- Agnieszka Troszok
- Institute of Ichthyobiology and Aquaculture, Polish Academy of Sciences, Chybie, Poland
| | - Ludmiła Kolek
- Institute of Ichthyobiology and Aquaculture, Polish Academy of Sciences, Chybie, Poland
| | - Joanna Szczygieł
- Institute of Ichthyobiology and Aquaculture, Polish Academy of Sciences, Chybie, Poland
| | - Joanna Wawrzeczko
- Institute of Ichthyobiology and Aquaculture, Polish Academy of Sciences, Chybie, Poland
| | - Ewa Borzym
- Department of Fish Diseases, National Veterinary Research Institute in Puławy, Puławy, Poland
| | - Michał Reichert
- Department of Fish Diseases, National Veterinary Research Institute in Puławy, Puławy, Poland
| | - Teresa Kamińska
- Institute of Ichthyobiology and Aquaculture, Polish Academy of Sciences, Chybie, Poland
| | - Tomasz Ostrowski
- Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznań, Poland
| | - Patrycja Jurecka
- Institute of Ichthyobiology and Aquaculture, Polish Academy of Sciences, Chybie, Poland
| | - Mikołaj Adamek
- Fish Disease Research Unit, University of Veterinary Medicine, Hannover, Germany
| | - Krzysztof Rakus
- Department of Evolutionary Immunology, Institute of Zoology and Biomedical Research, Jagiellonian University, Kraków, Poland
| | - Ilgiz Irnazarow
- Institute of Ichthyobiology and Aquaculture, Polish Academy of Sciences, Chybie, Poland
| |
Collapse
|
29
|
Abstract
EPM, CVSM, and EDM are currently recognized as the 3 most common neurologic diseases in US horses, with the latter 2 conditions being most prevalent in young animals. Moreover, horses competing at shows and performance events are at greater risk for exposure to highly contagious, neurologic EHV-1 outbreaks. A clinical diagnosis of any neurologic disease should be based on a careful history, complete neurologic examination, and appropriate diagnostic testing and interpretation. However, mild or early neurologic signs can often mimic or be mistaken for an orthopedic condition when horses present for performance-related concerns.
Collapse
|
30
|
Easton-Jones CA, Madigan JE, Barnum S, Maxwell LK, Taylor SD, Arnesen T, Pusterla N. Effect of valacyclovir on EHV-5 viral kinetics in horses with equine multinodular pulmonary fibrosis. J Vet Intern Med 2018; 32:1763-1767. [PMID: 30221792 PMCID: PMC6189341 DOI: 10.1111/jvim.15230] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Revised: 04/10/2018] [Accepted: 05/02/2018] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND Equine herpesvirus-5 is commonly isolated from the lungs of horses with EMPF, suggesting an etiological link. Valacyclovir is used empirically to treat EMPF; however, no data is available concerning its impact on EHV-5 viral kinetics. OBJECTIVES To determine the effect of oral administration of valacyclovir on EHV-5 viral load measured by qPCR in blood, nasal secretions (NS) and BALF in horses with EMPF. ANIMALS Six horses diagnosed with EMPF. METHODS A prospective clinical trial was performed. Horses received 10 days of PO administered valacyclovir (loading dose 30 mg/kg, maintenance dose 20 mg/kg). Blood, NS, and BALF were collected for EHV-5 viral kinetics analyses during treatment. Blood and NS were collected every other day. BALF was collected on day 0 and day 10. RESULTS There was no statistical difference in median EHV-5 viral load between day 0 and day 10 for all samples tested. In blood median EHV-5 viral load was 7676 (range 575-39 781) on day 0 and 6822 (range 1136-18 635) glycoprotein B (gB) gene copies per million cells on day 10. For NS median EHV-5 viral load was 2.944 × 106 (range 184 691-3.394 × 109 ) on day 0 and 8.803 × 106 (range 251 186-9.868 × 108 ) gB gene copies per million cells on day 10. For BALF median EHV-5 viral load was 59,842 (range 61-315 655) on day 0 and 185 083 (range 3562-542 417) gB gene copies per million cells on day 10. CONCLUSIONS AND CLINICAL IMPORTANCE Valacyclovir might not be an effective short-term antiviral treatment but efficacy in treatment of EMPF is unknown.
Collapse
Affiliation(s)
- Charlotte A Easton-Jones
- Willian R Pritchard Veterinary Medical Teaching Hospital, University of California Davis, California
| | - John E Madigan
- Department of Medicine and Epidemiology, University of California, Davis, California
| | - Samantha Barnum
- Department of Medicine and Epidemiology, University of California, Davis, California
| | - Lara K Maxwell
- Department of Physiological Sciences, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, Oklahoma
| | - Sandra D Taylor
- Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, Indiana, IN
| | - Terry Arnesen
- Stillwater Equine Veterinary Clinic, Stillwater, Minnesota
| | - Nicola Pusterla
- Department of Medicine and Epidemiology, University of California, Davis, California
| |
Collapse
|
31
|
Stokol T, Serpa PBS, Brooks MB, Divers T, Ness S. Subcutaneous Administration of Low-Molecular-Weight Heparin to Horses Inhibits Ex Vivo Equine Herpesvirus Type 1-Induced Platelet Activation. Front Vet Sci 2018; 5:106. [PMID: 29892605 PMCID: PMC5985713 DOI: 10.3389/fvets.2018.00106] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2017] [Accepted: 04/30/2018] [Indexed: 01/28/2023] Open
Abstract
Equine herpesvirus type 1 (EHV-1) is a major cause of infectious respiratory disease, abortion and neurologic disease. Thrombosis in placental and spinal vessels and subsequent ischemic injury in EHV-1-infected horses manifests clinically as abortion and myeloencephalopathy. We have previously shown that addition of heparin anticoagulants to equine platelet-rich plasma (PRP) can abolish ex vivo EHV-1-induced platelet activation. The goal of this study was to test whether platelets isolated from horses treated with unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) were resistant to ex vivo EHV-1-induced activation. In a masked, block-randomized placebo-controlled cross-over trial, 9 healthy adult horses received 4 subcutaneous injections at q. 12 h intervals of one of the following treatments: UFH (100 U/kg loading dose, 3 maintenance doses of 80 U/kg), 2 doses of LMWH (enoxaparin) 80 U/kg 24 h apart with saline at the intervening 12 h intervals, or 4 doses of saline. Blood samples were collected before treatment and after 36 h, 40 h (4 h after the last injection) and 60 h (24 h after the last injection). Two strains of EHV-1, Ab4 and RacL11, were added to PRP ex vivo and platelet membrane expression of P selectin was measured as a marker of platelet activation. Drug concentrations were monitored in a Factor Xa inhibition (anti-Xa) bioassay. We found that LMWH, but not UFH, inhibited platelet activation induced by low concentrations (1 × 106 plaque forming units/mL) of both EHV-1 strains at 40 h. At this time point, all horses had anti-Xa activities above 0.1 U/ml (range 0.15-0.48 U/ml) with LMWH, but not UFH. By 60 h, a platelet inhibitory effect was no longer detected and anti-Xa activity had decreased (range 0.03 to 0.07 U/ml) in LMWH-treated horses. Neither heparin inhibited platelet activation induced by high concentrations (5 × 106 plaque forming units/mL) of the RacL11 strain. We found substantial between horse variability in EHV-1-induced platelet activation at baseline and after treatment. Minor injection site reactions developed in horses given either heparin. These results suggest that LMWH therapy may prevent thrombotic sequelae of EHV-1, however further evaluation of dosage regimens is required.
Collapse
Affiliation(s)
- Tracy Stokol
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States
| | - Priscila B S Serpa
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States
| | - Marjory B Brooks
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States
| | - Thomas Divers
- Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States
| | - Sally Ness
- Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States
| |
Collapse
|